Novel Diagnostics With Optical Coherence Tomography: Retinal Imaging

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
National Eye Institute (NEI)
Information provided by (Responsible Party):
New York University School of Medicine
ClinicalTrials.gov Identifier:
NCT00343746
First received: June 19, 2006
Last updated: January 11, 2017
Last verified: January 2017
  Purpose
The purpose of this research is to evaluate optical coherence tomography (OCT) and FDA approved device used to image diseases of the eye. The ultra-high resolution OCT is a non-significant risk device used in this study. Optical Coherence Tomography may be useful for early diagnosis and monitoring of different types of eye diseases.

Condition Phase
Macular Degeneration
Glaucoma
Diabetic Retinopathy
Phase 1

Study Type: Observational
Official Title: Novel Diagnostics With Optical Coherence Tomography: Retinal Imaging

Resource links provided by NLM:


Further study details as provided by New York University School of Medicine:

Primary Outcome Measures:
  • Novel Diagnostics With Optical Coherence Tomography: Retinal Imaging [ Time Frame: 2 years ]
    The purpose of this research is to evaluate optical coherence tomography (OCT) and FDA approved device used to image diseases of the eye. The ultra-high resolution OCT is a non-significant risk device used in this study. Optical Coherence Tomography may be useful for early diagnosis and monitoring of different types of eye diseases.


Enrollment: 1009
Study Start Date: October 2005
Estimated Study Completion Date: January 2020
Estimated Primary Completion Date: January 2017 (Final data collection date for primary outcome measure)
Detailed Description:
The purpose of this research is to evaluate optical coherence tomography (OCT) and FDA approved device used to image diseases of the eye. The ultra-high resolution OCT is a non-significant risk device used in this study. OCT may be useful for early diagnosis and monitoring of different types of eye diseases.
  Eligibility

Ages Eligible for Study:   18 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Subjects can be 18 to 90 years of age. They can be male or female. Recruiting for normal and diseased subjects.
Criteria

Inclusion Criteria:

  • Subjects with healthy eyes, macular degeneration, glaucoma and other various eye diseases. Also must be able to fixate on target.

Exclusion Criteria:

  • If the fundus is not visible if the media is opaque and if they are unwilling to participate.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00343746

Locations
United States, Pennsylvania
University of Pittsburgh UPMC Eye Center
Pittsburgh, Pennsylvania, United States, 15213
Sponsors and Collaborators
New York University School of Medicine
National Eye Institute (NEI)
Investigators
Study Chair: Joel S Schuman, MD University of Pittsburgh
Study Director: Gadi Wollstein, MD University of Pittsburgh
Principal Investigator: Ian Conner, MD, PhD University of Pittsburgh
  More Information

Responsible Party: New York University School of Medicine
ClinicalTrials.gov Identifier: NCT00343746     History of Changes
Other Study ID Numbers: 0309021  R01EY011289-15 
Study First Received: June 19, 2006
Last Updated: January 11, 2017
Individual Participant Data  
Plan to Share IPD: Undecided

Keywords provided by New York University School of Medicine:
macular degeneration
glaucoma
diabetic retinopathy
retinopathy, eye diseases

Additional relevant MeSH terms:
Macular Degeneration
Glaucoma
Retinal Diseases
Diabetic Retinopathy
Retinal Degeneration
Eye Diseases
Ocular Hypertension
Diabetic Angiopathies
Vascular Diseases
Cardiovascular Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases

ClinicalTrials.gov processed this record on January 19, 2017